Zhouyanjie Zhou

Ms. Zhouyanjie Zhou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSShiya Shi
Shiya Shi
ZZZhouyanjie Zhou
Zhouyanjie Zhou
HZHe Zhang
He Zhang
YZYalan Zhu
Yalan Zhu
PJPengjun Jiang
Pengjun Jiang
JCjie chen
jie chen
Background: Observational studies have highlighted the pivotal role of inflammatory cytokines in cirrhosis progression. However, the existence of a causal link between inflammatory cytokines and cirrhosis remains uncertain. In this study, we conducted a bidirectional Mendelian randomization (MR) analysis at a summarized level to illuminate the potential causal relationship between the two variables. Methods: This study utilized genetic variance in cirrhosis and inflammatory cytokines from a genome-wide association study (GWAS) of European descent. The MR-PRESSO outlier test, Cochran’s Q test, and MR-Egger regression were applied to assess outliers, heterogeneity, and pleiotropy. The inverse variance weighted method and multiple sensitivity analyses were used to evaluate causalities. Furthermore, the validation set was used for simultaneous data validation. Results: The inflammatory cytokine monocyte chemoattractant protein 3 (MCP-3) was supposedly associated with a greater risk of cirrhosis. And cirrhosis was significantly correlated with increased levels of hepatocyte growth factor (HGF). Conclusions: This study suggests that MCP-3 might be associated with the etiology of cirrhosis, while several inflammatory cytokines could potentially play a role in its downstream development. Additionally, the progression of cirrhosis was associated with elevated levels of HGF, suggesting a possible role for liver repair functions.

Verified
Open access
ZZZhouyanjie Zhou
Zhouyanjie Zhou
禾张禾 张
禾 张
亚朱亚兰 朱
亚兰 朱
鹏蒋鹏骏 蒋
鹏骏 蒋
天丰天宇 丰
天宇 丰
捷陈捷 陈
捷 陈
探讨mutY同源物(mutY homolog, MUTYH)基因在肝细胞癌(hepatocellular carcinoma, HCC)中的表达情况、预后价值及潜在作用机制,分析其作为HCC新型生物标志物和治疗靶点的临床转化潜力。 通过TCGA、GEO数据库对比MUTYH在HCC与正常组织中的表达差异,并分析其与临床病理参数、TP53突变、甲胎蛋白(alpha-fetoprotein, AFP)诊断效能及索拉非尼耐药性的关系;通过Kaplan-Meier法和log-rank检验进行生存分析评估预后影响,采用单变量和多变量Cox比例风险回归模型分析其独立预后价值;通过 GO、KEGG、GESA富集分析和PPI网络解析其分子机制;利用CIBERSORT算法和BEST数据库分析MUTYH与免疫细胞浸润、免疫检查点抑制剂疗效的关系;采用实时荧光定量 PCR(quantitative real-time polymerase chain reaction, qPCR)验证MUTYH和其核心关联分子在HCC组织与正常组织中的表达差异。 MUTYH在HCC组织中异常高表达(P<0.05), 临床样本检测证实其可作为诊断HCC的生物标志物〔曲线下面积(area under the curve, AUC)=0.824,95%置信区间(confidence interval, CI):0.762~0.886,P<0.001〕,其在低AFP表达的HCC亚组中仍表现出较高的诊断价值(GSE25097:AUC=0.716,P<0.001;GSE63898:AUC=0.624,P<0.001)。MUTYH高表达与索拉非尼耐药相关(P<0.05),且是影响患者总生存期的独立危险因素〔风险比(hazard ratio, HR):1.92,P<0.05〕。功能富集分析表明MUTYH参与细胞周期调控等信号通路,并与脱嘌呤/脱嘧啶核酸内切酶 1(apurinic/apyrimidinic endonuclease 1, APEX1)表达呈正相关(GSE157142:r=0.83,P<0.05),可能通过调控G1/S期关键分子(细胞周期蛋白依赖性激酶 4,细胞周期蛋白依赖性激酶 7,细胞周期蛋白 E2)促进细胞周期进程。免疫浸润分析显示MUTYH与肿瘤微环境中多种免疫细胞水平相关,并能有效预测抗 PD-1/PD-L1治疗响应(IMvigor210队列和Cho2020队列AUC分别为0.637和0.782),但与抗CTLA-4治疗无统计学关联。 HCC中MUTYH表达显著升高,分析发现MUTYH可通过调控APEX1及细胞周期关键分子促进HCC发展;其诊断与预后评估效能优于传统标志物AFP,并与患者抗PD-1/PD-L1治疗响应、索拉非尼耐药性相关。综上,MUTYH有潜力成为HCC新型生物标志物及治疗靶点。